R
Robert Elling
Researcher at Novartis
Publications - 8
Citations - 637
Robert Elling is an academic researcher from Novartis. The author has contributed to research in topics: Internal medicine & Lipid A. The author has an hindex of 7, co-authored 7 publications receiving 466 citations.
Papers
More filters
Journal ArticleDOI
Selective VPS34 inhibitor blocks autophagy and uncovers a role for NCOA4 in ferritin degradation and iron homeostasis in vivo
William E. Dowdle,Beat Nyfeler,Jane Nagel,Robert Elling,Shanming Liu,Ellen Triantafellow,Suchithra Menon,Zuncai Wang,Ayako Honda,Gwynn Pardee,John Cantwell,Catherine Luu,Ivan Cornella-Taracido,Edmund Harrington,Peter Fekkes,Hong Lei,Qing Fang,Mary Ellen Digan,Debra Burdick,Andrew F. Powers,Stephen B. Helliwell,Simon D’Aquin,Julie Bastien,Henry Wang,Dmitri Wiederschain,Jenny Kuerth,Philip Bergman,David Schwalb,Jason R. Thomas,Savuth Ugwonali,Fred Harbinski,John A. Tallarico,Christine D. Wilson,Vic E. Myer,Jeffery A. Porter,Dirksen E. Bussiere,Peter Finan,Mark Labow,Xiaohong Mao,Lawrence G. Hamann,Brendan D. Manning,Reginald Valdez,Thomas B. Nicholson,Markus Schirle,Mark Knapp,Erin P. Keaney,Leon Murphy +46 more
TL;DR: a4−/− mice exhibit a profound accumulation of iron in splenic macrophages, which are critical for the reutilization of iron from engulfed red blood cells, and a previously unappreciated role for autophagy and NCOA4 in the control of iron homeostasis in vivo is revealed.
Journal ArticleDOI
Structure-Based Drug Design of Novel Potent and Selective Tetrahydropyrazolo[1,5-a]pyrazines as ATR Inhibitors.
Paul A. Barsanti,Robert J. Aversa,Xianming Jin,Yue Pan,Yipin Lu,Robert Elling,Rama Jain,Mark Knapp,Jiong Lan,Xiaodong Lin,Patrick J Rudewicz,Janet Sim,Lorena Taricani,George Thomas,Linda Xiao,Qin Yue +15 more
TL;DR: A saturation strategy focused on improving the selectivity and physicochemical properties of ATR inhibitor HTS hit 1 led to a novel series of highly potent and selective tetrahydropyrazolo[1,5-a]pyrazines.
Journal ArticleDOI
Potent nonimmunosuppressive cyclophilin inhibitors with improved pharmaceutical properties and decreased transporter inhibition.
Jiping Fu,Meiliana Tjandra,Christopher Becker,Dallas Bednarczyk,Michael Paul Capparelli,Robert Elling,Imad Hanna,Roger Aki Fujimoto,Markus Furegati,Subramanian Karur,Theresa Kasprzyk,Mark Knapp,Kwan Leung,Xiaolin Li,Peichao Lu,Wosenu Mergo,Charlotte Miault,Simon Ng,David Thomas Parker,Yunshan Peng,Silvio Roggo,Alexey Rivkin,Robert Lowell Simmons,Michael Wang,Brigitte Wiedmann,Andrew H. Weiss,Linda Xiao,Lili Xie,Wenjian Xu,Aregahegn Yifru,Shengtian Yang,Bo Zhou,Zachary Kevin Sweeney +32 more
TL;DR: In this article, the side chain hydrophobicity of the P4 residue of cyclophilin D has been reduced to preserve binding and antiviral potency while decreasing transporter inhibition.
Journal ArticleDOI
Structure-guided enzymology of the lipid A acyltransferase LpxM reveals a dual activity mechanism.
Dustin Dovala,Christopher M. Rath,Qijun Hu,William S. Sawyer,Steven Shia,Robert Elling,Mark Knapp,Louis E. Metzger +7 more
TL;DR: This work structurally and mechanistically characterize LpxM, providing insights that may enable the targeted discovery of inhibitors that prevent lipid A maturation, and describes a high-throughput, label-free mass spectrometric assay to characterize acyltransferase enzymatic activity.
Journal ArticleDOI
Discovery of imidazo[1,2-a]-pyridine inhibitors of pan-PI3 kinases that are efficacious in a mouse xenograft model.
Wooseok Han,Daniel Menezes,Yongjin Xu,Mark Knapp,Robert Elling,Matthew Burger,Zhi-Jie Ni,Aaron Smith,Jiong Lan,Teresa E. Williams,Joelle Verhagen,Kay Huh,Hanne Merritt,John Chan,Susan Kaufman,Charles Voliva,Sabina Pecchi +16 more
TL;DR: Imidazopyridine compound 1, a potent, selective, and orally available pan-PI3K inhibitor, was further optimized in order to achieve efficacy in a PTEN-deleted A2780 ovarian cancer mouse xenograft model.